<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Elnabawi YA</submitter><funding>National Psoriasis Foundation</funding><funding>American Heart Association</funding><funding>NCATS NIH HHS</funding><funding>Rheumatology Research Foundation</funding><funding>NHLBI NIH HHS</funding><funding>Dermatology Foundation</funding><funding>American Society of Hematology</funding><funding>National Institutes of Health</funding><funding>NIAMS NIH HHS</funding><pagination>913-920</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8049184</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>84(4)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Psoriasis is associated with increased cardiovascular risk that is not captured by traditional proinflammatory biomarkers.&lt;h4>Objective&lt;/h4>To investigate the relationship between Psoriasis Area and Severity Index, circulating proinflammatory biomarkers, and vascular health in psoriasis.&lt;h4>Methods&lt;/h4>In patients with psoriasis and in age and sex-matched controls, 273 proteins were analyzed with the Proseek Multiplex Cardiovascular disease reagents kit and Inflammatory reagents kit (Olink Bioscience), whereas vascular endothelial inflammation and health were measured via direct transcriptomic analysis of brachial vein endothelial cells.&lt;h4>Results&lt;/h4>In psoriasis, chemokine ligand 20 (CCL20), interleukin (IL) 6, and IL-17A were the top 3 circulating proinflammatory cyt</pubmed_abstract><journal>Journal of the American Academy of Dermatology</journal><pubmed_title>CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health.</pubmed_title><pmcid>PMC8049184</pmcid><funding_grant_id>UL1 TR000040</funding_grant_id><funding_grant_id>L30 HL143703</funding_grant_id><funding_grant_id>R01 HL139909</funding_grant_id><funding_grant_id>R35 HL144993</funding_grant_id><funding_grant_id>UL1 TR001445</funding_grant_id><funding_grant_id>UL1 TR000038</funding_grant_id><funding_grant_id>R01 HL114978</funding_grant_id><funding_grant_id>KL2 TR001446</funding_grant_id><funding_grant_id>T32 HL098129</funding_grant_id><funding_grant_id>K23 HL152013</funding_grant_id><funding_grant_id>KL2 TR000053</funding_grant_id><funding_grant_id>T32 HL007343</funding_grant_id><funding_grant_id>TL1 TR001447</funding_grant_id><funding_grant_id>R01 AR074500</funding_grant_id><pubmed_authors>Scher JU</pubmed_authors><pubmed_authors>Elnabawi YA</pubmed_authors><pubmed_authors>Lo Sicco K</pubmed_authors><pubmed_authors>Tawil M</pubmed_authors><pubmed_authors>Krueger J</pubmed_authors><pubmed_authors>Garshick MS</pubmed_authors><pubmed_authors>Barrett TJ</pubmed_authors><pubmed_authors>Neimann AL</pubmed_authors><pubmed_authors>Berger JS</pubmed_authors><pubmed_authors>Fisher EA</pubmed_authors></additional><is_claimable>false</is_claimable><name>CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health.</name><description>&lt;h4>Background&lt;/h4>Psoriasis is associated with increased cardiovascular risk that is not captured by traditional proinflammatory biomarkers.&lt;h4>Objective&lt;/h4>To investigate the relationship between Psoriasis Area and Severity Index, circulating proinflammatory biomarkers, and vascular health in psoriasis.&lt;h4>Methods&lt;/h4>In patients with psoriasis and in age and sex-matched controls, 273 proteins were analyzed with the Proseek Multiplex Cardiovascular disease reagents kit and Inflammatory reagents kit (Olink Bioscience), whereas vascular endothelial inflammation and health were measured via direct transcriptomic analysis of brachial vein endothelial cells.&lt;h4>Results&lt;/h4>In psoriasis, chemokine ligand 20 (CCL20), interleukin (IL) 6, and IL-17A were the top 3 circulating proinflammatory cyt</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Apr</publication><modification>2025-04-29T11:28:06.293Z</modification><creation>2025-04-29T11:28:06.293Z</creation></dates><accession>S-EPMC8049184</accession><cross_references><pubmed>33259876</pubmed><doi>10.1016/j.jaad.2020.10.094</doi></cross_references></HashMap>